User: prashantiyengar Topic: IP
Category: drugs :: india
Last updated: Oct 31 2014 06:00 IST RSS 2.0
 
1 to 20 of 2,451    
Roche-Cipla patent row mediation fails 31.10.2014 TOI: India Business
Efforts to end the long and bitter patent tussle between domestic pharma company Cipla and multinational Roche over a lung cancer drug have come to a naught, with the Delhi high court-appointed mediator submitting its “failure” report in the case.
Also found in: [+]
Cipla asks government to revoke Novartis' patent; launches its drug 30.10.2014 ET: Pharma
Cipla has launched low-cost generic version of Novartis's respiratory drug Indacaterol while asking government to revoke patents over the medicine.
Also found in: [+]
Cipla asks government to revoke Novartis patents on respiratory drug 30.10.2014 Sify Finance
Also found in: [+]
Cipla asks government to cancel Novartis patents on respiratory drug 30.10.2014 ET: Pharma
Onbrez, chemically called indicaterol, is used to treat breathing problems associated with chronic obstructive pulmonary disease.
Also found in: [+]
Cipla asks government to revoke five patents held by Novartis 30.10.2014 ET: Pharma
Cipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug Onbrez.
Also found in: [+]
Indian drugmakers asks US Trade Representative body to restore faith in new trade policy 30.10.2014 ET: Pharma
Indian Pharma Alliance, a grouping of top domestic drugmakers, in its latest submission has urged the USTR to consider submissions of many American firms across sectors.
Also found in: [+]
India, China to command 70% of $20-bn global biosimilars market 28.10.2014 Sify Finance
India and China would together command around 70 per cent of the $20-billion global biosimilars market, supported by low-cost manufacturing, less expenditure incurred on research and development
Also found in: [+]
Subramanian till recently had opposed India on IPR 25.10.2014 India News, Latest News in India, Live News India, India Breaking News - Times of India
Subramanian was a senior fellow at the Peterson Institute for International Economics and at the Center for Global ...
Also found in: [+]
Govt sets up 6-member IPR think tank 25.10.2014 TOI: India Business
Taking into account India’s dismal performance in protecting intellectual property rights over drug and agricultural products, the Centre has formed a six-member ‘think tank’ to draft national IPR policy and suggest legal means to handle undue pressure exerted by other countries on this issue.
Also found in: [+]
DIPP sets up think tank to draft national Intellectual Property Rights policy 24.10.2014 ET: Policy
It will keep the government regularly informed about the developments taking place in IPR cases which have an impact upon India's IPR Policy, it said.
Also found in: [+]
40 years ago and now: How Ranbaxy moved out of family control 22.10.2014 Rediff: Business
Ranbaxy did its maiden public issue in 1973.
Also found in: [+]
Government may propose sub-groups on other contentious issues under ambit of IPR panel 22.10.2014 ET: Pharma
During PM Modi’s visit to the US, the two countries committed to set up an annual high-level IP working group as part of the trade policy forum.
Also found in: [+]
Pharma companies feel law change can weaken ability to provide low-cost drugs 21.10.2014 ET: Pharma
Indian drugmakers are also concerned about a shift in India’s position on IPR, which they say is being keenly watched by many developing countries.
Also found in: [+]
DIPP seeks details on blood cancer drug Dasatinib for issuance of compulsory licences 19.10.2014 ET: Pharma
The ministry has sought details from the Health Ministry, which had approached the DIPP for issuance of compulsory licences.
Also found in: [+]
Medical charity accuses US of pushing India to ease patent rules 18.10.2014 ET: Pharma
India's stringent rules for obtaining patents and its $12.2-billion generics industry reduce incentives to produce cutting-edge medicines.
Also found in: [+]
DIPP defers decision on issuance of compulsory licence for cancer drug Dasatinib 16.10.2014 ET: Pharma
“DIPP has sought further information to justify the issuance of a CL under Section 92 of Indian Patents Act,” said an official privy to the matter."
Also found in: [+]
US to launch fresh review of India's patent regime 14.10.2014 ET: Policy
US Trade Representative has launched a fresh offensive against India's intellectual property rights regime, a move that may hamper bilateral dialogue with US.
Also found in: [+]
An old policy Modi must hold on to 14.10.2014 India Together

The government’s clarification on the Indo-US joint statement on Intellectual Property Rights issued during Modi’s visit to the United States highlights the imperative of maintaining India’s original stance on patent laws and refusal to yield to US demands made in its Special 301 Report. Shambhu Ghatak has more.

Also found in: [+]
US to launch fresh review of India's patent regime 14.10.2014 TOI: India Business
An OCR is a second stage of the Special 301 action and being an extreme measure, the US authorities can impose sanctions after putting the country in the "priority foreign watch" category.
Also found in: [+]
Over the counter drug market to reach $6.6 billion by 2016 5.10.2014 ET: Pharma
Pharma companies have increased spending to tap rural markets. The market share of hospitals is expected to increase from 13.1& in 2009 to 26% in 2020
Also found in: [+]
1 to 20 of 2,451